The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Cardiotoxicity of anticancer treatments
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8807 · Cited by 3,304
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,775
Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., Barrios, C. H., Salman, P., Gladkov, O. A., Kavina, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9764 · Cited by 2,471
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Self-citationIdentification of the molecular basis of doxorubicin-induced cardiotoxicity
Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L.-S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. H. (2012) · Nature Medicine · doi:10.1038/nm.2919 · Cited by 1,948
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., et al. (2014) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2014.07.012 · Cited by 1,795
Self-citationA clinicopathologic analysis of adriamycin cardiotoxicity
Lefrak, E. A., Piťha, J., Rosenheim, S., & Gottlieb, J. A. (1973) · Cancer · doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2 · Cited by 1,560
Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241205 · Cited by 1,404
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
Joensuu, H., Kellokumpu-Lehtinen, P.-L., Bono, P., Alanko, T., Kataja, V., Asola, R., Utriainen, T., Kokko, R., Hemminki, A., Tarkkanen, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053028 · Cited by 1,403
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Kerkelä, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1446 · Cited by 1,159
Cardinale, D., Colombo, A., Sandri, M. T., Lamantia, G., Colombo, N., Civelli, M., Martinelli, G., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2006) · Circulation · doi:10.1161/circulationaha.106.635144 · Cited by 1,026
Scappaticci, F. A., Skillings, J. R., Holden, S. N., Gerber, H.-P., Miller, K., Kabbinavar, F., Bergsland, E., Ngai, J., Holmgren, E., Wang, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm086 · Cited by 938
ErbB2 is essential in the prevention of dilated cardiomyopathy
Crone, S. A., Zhao, Y.-Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., Peterson, K. L., Chen, J., Kahn, R., Condorelli, G., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-459 · Cited by 903
Tan-Chiu, E., Yothers, G., Romond, E., Geyer, C. E., Ewer, M., Keefe, D., Shannon, R. P., Swain, S. M., Brown, A., Fehrenbacher, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4091 · Cited by 808
Self-citationFactors Affecting Late Mortality From Heart Disease After Treatment of Hodgkin's Disease
Hancock, S. L. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510160067031 · Cited by 773
Ewer, M. S., Vooletich, M. T., Durand, J.-B., Woods, M. L., Davis, J. R., Valero, V., & Lenihan, D. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.300 · Cited by 726
Self-citationProtective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy
Kalay, N., Basar, E., Ozdogru, I., Er, O., Cetinkaya, Y., Dogan, A., Oguzhan, A., Eryol, N. K., Topsakal, R., Ergin, A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.052 · Cited by 713
Prevention of Anthracycline-Induced Cardiotoxicity
Vejpongsa, P., & Yeh, E. T. H. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.06.1167 · Cited by 671
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S., York, M., Spicer, D., Jones, S. E., Wadler, S., Desai, A., Vogel, C., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1318 · Cited by 664
Self-citationType II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity
Ewer, M. S., & Lippman, S. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.827 · Cited by 646
Self-citationBosch, X., Rovira, M., Sitges, M., Domènech, A., Ortiz-Pérez, J. T., de Caralt, T. M., Morales-Ruiz, M., Perea, R. J., Monzó, M., & Esteve, J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.072 · Cited by 632
Effect of anthracycline antibiotics on oxygen radical formation in rat heart.
Doroshow, J. H. (1983) · PubMed · Cited by 629
Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Schmidinger, M., Zielinski, C. C., Vogl, U. M., Bojic, A., Bojic, M., Schukro, C., Ruhsam, M., Hejna, M., & Schmidinger, H. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6331 · Cited by 615
Anthracycline cardiomyopathy monitored by morphologic changes.
Billingham, M. E., Mason, J. W., Bristow, M. R., & Daniels, J. R. (1978) · PubMed · Cited by 586
Rini, B. I., Cohen, D. P., Lu, D. R., Chen, I., Hariharan, S., Gore, M. E., Figlin, R. A., Baum, M. S., & Motzer, R. J. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr128 · Cited by 579
Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial
Suter, T. M., Procter, M., van Veldhuisen, D. J., Muscholl, M., Bergh, J., Carlomagno, C., Perren, T., Passalacqua, R., Bighin, C., Klijn, J. G. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1611 · Cited by 566
Perez, E. A., Suman, V. J., Davidson, N. E., Sledge, G. W., Kaufman, P. A., Hudis, C. A., Martino, S., Gralow, J. R., Dakhil, S. R., Ingle, J. N., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5467 · Cited by 538
Romond, E. H., Jeong, J.-H., Rastogi, P., Swain, S. M., Geyer, C. E., Ewer, M. S., Rathi, V., Fehrenbacher, L., Brufsky, A., Azar, C. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.0010 · Cited by 520
Self-citationRadiation-associated cardiovascular disease
Adams, M. J., Hardenbergh, P. H., Constine, L. S., & Lipshultz, S. E. (2003) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00227-x · Cited by 506
Goldhirsch, A., Gelber, R. D., Piccart-Gebhart, M. J., de Azambuja, E., Procter, M., Suter, T. M., Jackisch, C., Cameron, D., Weber, H. A., Heinzmann, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61094-6 · Cited by 497
Cardiotoxicity Associated With High-Dose Cyclophosphamide Therapy
Gottdiener, J. S. (1981) · Archives of Internal Medicine · doi:10.1001/archinte.141.6.758 · Cited by 486
Brosius, F. C., Waller, B. F., & Roberts, W. C. (1981) · The American Journal of Medicine · doi:10.1016/0002-9343(81)90574-x · Cited by 473
Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy
Özcelik, C., Erdmann, B., Pilz, B., Wettschureck, N., Britsch, S., Hübner, N., Chien, K. R., Birchmeier, C., & Garratt, A. N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122249299 · Cited by 473
Cancer drugs and the heart: importance and management
Suter, T. M., & Ewer, M. S. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs181 · Cited by 472
Self-citationWouters, K. A., Kremer, L. C. M., Miller, T. L., Herman, E. H., & Lipshultz, S. E. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05759.x · Cited by 453
Lipshultz, S. E., Scully, R. E., Lipsitz, S. R., Sallan, S. E., Silverman, L. B., Miller, T. L., Barry, E. V., Asselin, B. L., Athale, U., Clavell, L. A., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70204-7 · Cited by 446
Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials
Perez, E. A., Koehler, M., Byrne, J., Preston, A. J., Rappold, E., & Ewer, M. S. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60896-3 · Cited by 388
Self-citationTrastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of Reversibility
Telli, M. L., Hunt, S. A., Carlson, R. W., & Guardino, A. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0106 · Cited by 385
Cardiotoxicity of anticancer treatments: what the cardiologist needs to know
Ewer, M. S., & Ewer, S. M. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.121 · Cited by 373
Self-citationGuarneri, V., Lenihan, D. J., Valero, V., Durand, J.-B., Broglio, K., Hess, K. R., Michaud, L. B., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Esteva, F. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9551 · Cited by 361
Kalam, K., & Marwick, T. H. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.04.030 · Cited by 343
Radiation-Induced Heart Disease: Pathologic Abnormalities and Putative Mechanisms
Taunk, N. K., Haffty, B. G., Kostis, J. B., & Goyal, S. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00039 · Cited by 316
Kozloff, M., Yood, M. U., Berlin, J., Flynn, P. J., Kabbinavar, F. F., Purdie, D. M., Ashby, M. A., Dong, W., Sugrue, M. M., Grothey, A., et al. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0071 · Cited by 305
Anthracyclines Induce Calpain-dependent Titin Proteolysis and Necrosis in Cardiomyocytes
Lim, C. C., Zuppinger, C., Guo, X., Kuster, G. M., Helmes, M., Eppenberger, H. M., Suter, T. M., Liao, R., & Sawyer, D. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m308033200 · Cited by 304
Henson, K. E., McGale, P., Taylor, C., & Darby, S. C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.575 · Cited by 287
Different anthracycline derivates for reducing cardiotoxicity in cancer patients
van Dalen, E. C., Michiels, E. M. C., Caron, H. N., & Kremer, L. C. M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005006.pub4 · Cited by 265
Screening for Coronary Artery Disease After Mediastinal Irradiation for Hodgkin's Disease
Heidenreich, P. A., Schnittger, I., Strauss, H. W., Vagelos, R. H., Lee, B. K., Mariscal, C. S., Tate, D. J., Horning, S. J., Hoppe, R. T., & Hancock, S. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0805 · Cited by 262
Congestive heart failure is a rare event in patients receiving imatinib therapy
Atallah, E., Durand, J.-B., Kantarjian, H., & Cortes, J. (2007) · Blood · doi:10.1182/blood-2007-01-070144 · Cited by 252
Adriamycin cardiomyopathy—risk factors
Minow, R. A., Benjamin, R. S., Lee, E. T., & Gottlieb, J. A. (1977) · Cancer · doi:10.1002/1097-0142(197704)39:4<1397::aid-cncr2820390407>3.0.co;2-u · Cited by 251
Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide
Westervelt, P., Brown, R. A., Adkins, D. R., Khoury, H., Curtin, P., Hurd, D., Luger, S. M., Ma, M. K., Ley, T. J., & DiPersio, J. F. (2001) · Blood · doi:10.1182/blood.v98.2.266 · Cited by 245
Ewer, M. S., Ali, M. K., Mackay, B., Wallace, S., Valdivieso, M., Legha, S. S., Benjamin, R. S., & Haynie, T. P. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.2.112 · Cited by 244
Self-citationKerkela, R., Woulfe, K. C., Durand, J., Vagnozzi, R., Kramer, D., Chu, T. F., Beahm, C., Chen, M. H., & Force, T. (2009) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2008.00090.x · Cited by 242
de Azambuja, E., Procter, M. J., van Veldhuisen, D. J., Agbor-Tarh, D., Metzger-Filho, O., Steinseifer, J., Untch, M., Smith, I. E., Gianni, L., Baselga, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.9288 · Cited by 235
Hall, P. S., Harshman, L. C., Srinivas, S., & Witteles, R. M. (2013) · JACC: Heart Failure · doi:10.1016/j.jchf.2012.09.001 · Cited by 207
De Keulenaer, G. W., Doggen, K., & Lemmens, K. (2010) · Circulation Research · doi:10.1161/circresaha.109.205906 · Cited by 201
Groarke, J. D., Nguyen, P. L., Nohria, A., Ferrari, R., Cheng, S., & Moslehi, J. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht114 · Cited by 193
Decline in the Use of Anthracyclines for Breast Cancer
Giordano, S. H., Lin, Y.-L., Kuo, Y. F., Hortobagyi, G. N., & Goodwin, J. S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1273 · Cited by 192
Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes
Lipshultz, S. E., Miller, T. L., Lipsitz, S. R., Neuberg, D. S., Dahlberg, S. E., Colan, S. D., Silverman, L. B., Henkel, J. M., Franco, V. I., Cushman, L. L., et al. (2012) · Pediatrics · doi:10.1542/peds.2012-0727 · Cited by 175
Swain, S. M., Ewer, M. S., Cortés, J., Amadori, D., Miles, D., Knott, A., Clark, E., Benyunes, M. C., Ross, G., & Baselga, J. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0448 · Cited by 163
Self-citationde Korte, M. A., de Vries, E. G. E., Lub-de Hooge, M. N., Jager, P. L., Gietema, J. A., van der Graaf, W. T. A., Sluiter, W. J., van Veldhuisen, D. J., Suter, T. M., Sleijfer, D. T., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.06.024 · Cited by 160
Chemotherapy-Induced Cardiotoxicity: Detection, Prevention, and Management
Truong, J., Yan, A. T.-K., Cramarossa, G., & Chan, K. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.04.029 · Cited by 131
Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer
Legha, S. S., Benjamin, R. S., Mackay, B., Yap, H. Y., Wallace, S., Ewer, M. S., Blumenschein, G. R., & Freireich, E. J. (1982) · Cancer · Cited by 94
Self-citationEwer, M. S., Suter, T. M., Lenihan, D. J., Niculescu, L., Breazna, A., Demetri, G. D., & Motzer, R. J. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.05.013 · Cited by 93
Self-citationGenotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity
Fan, L., Goh, B.-C., Wong, C., Sukri, N., Lim, S.-E., Tan, S., Guo, J.-Y., Lim, R., Yap, H., Khoo, Y.-M., et al. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328301a869 · Cited by 89
A Comparative Study of Doxorubicin and Epirubicin in Patients with Metastatic Breast Cancer
Hortobágyi, G. N., Yap, H. Y., Kau, S., Fraschini, G., Ewer, M. S., Chawla, S. P., & Benjamin, R. S. (1989) · American Journal of Clinical Oncology · doi:10.1097/00000421-198902000-00014 · Cited by 88
Self-citationCardio‐Oncology/Onco‐Cardiology
Hong, R., Iimura, T., Sumida, K. N. M., & Eager, R. M. (2010) · Clinical Cardiology · doi:10.1002/clc.20823 · Cited by 83
Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer
Pisano, C., Cecere, S. C., Napoli, M. D., Cavaliere, C., Tambaro, R., Facchini, G., Scaffa, C., Losito, S., Pizzolorusso, A., & Pignata, S. (2013) · Journal of Drug Delivery · doi:10.1155/2013/898146 · Cited by 80
Swain, S. M., Im, Y., Im, S., Chan, V. F., Miles, D. W., Knott, A., Clark, E., Ross, G. A., & Baselga, J. M. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0033 · Cited by 69
On behalf of the TOPS investigators, Baccarani, M., Druker, B. J., et al. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1566-2 · Cited by 60
Mughal, T. (2010) · Biologics: Targets & Therapy · doi:10.2147/btt.s5775 · Cited by 53
Underestimating Cardiac Toxicity in Cancer Trials: Lessons Learned?
Witteles, R. M., & Telli, M. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.4012 · Cited by 51
Pacciarini, M. A., Barbieri, B., Colombo, T., Broggini, M., Garattini, S. K., & Donelli, M. G. (1978) · PubMed · Cited by 50
Register, S. P., Takita, C., dos Reis, I. M., Zhao, W. K., Amestoy, W., & Wright, J. L. (2014) · Medical dosimetry · doi:10.1016/j.meddos.2014.10.005 · Cited by 49
Naing, A., Rodrigues, H. V., Hong, D. S., Fu, S., Falchook, G. S., Wheler, J. J., Tsimberidou, A. M., Wen, S., Fessahaye, S. N., Golden, E. C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds130 · Cited by 47
Self-citationKim, K. W., Shinagare, A. B., Krajewski, K. M., Pyo, J., Tirumani, S. H., Jagannathan, J. P., & Ramaiya, N. H. (2015) · Korean Journal of Radiology · doi:10.3348/kjr.2015.16.2.304 · Cited by 38
Cardiac Complications of Chemotherapy: Role of Biomarkers
Colombo, A., Sandri, M. T., Salvatici, M., Cipolla, C. M., & Cardinale, D. M. (2014) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-014-0313-6 · Cited by 32
Wong, M. K., & Jarkowski, A. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.4.473 · Cited by 26
Schonn, I., Hennesen, J., & Dartsch, D. C. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0564-y · Cited by 26
Chemotherapy and QT Prolongation: Overview With Clinical Perspective
Kim, P. Y., & Ewer, M. S. (2014) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-014-0303-8 · Cited by 20
Self-citationvan der Pal, H. J. H., van Dijk, I. W. E. M., Geskus, R. B., Kok, W. E. M., Koolen, M. I., Sieswerda, E., Oldenburger, F. R., Koning, C. C. E., van Leeuwen, F. E., Caron, H. N., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.09.010 · Cited by 20
Özkan, H. A., Bal, C., & Gülbaş, Z. (2013) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2013.12.001 · Cited by 19
Cited by
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Herrmann, J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0348-1 · Cited by 747
Gulati, G., Heck, S. L., Ree, A. H., Hoffmann, P., Schulz-Menger, J., Fagerland, M. W., Gravdehaug, B., von Knobelsdorff-Brenkenhoff, F., Bratland, Å., Storås, T. H., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw022 · Cited by 687
Atherton, J. J., Sindone, A., De Pasquale, C. G., Driscoll, A., MacDonald, P. S., Hopper, I., Kistler, P. M., Briffa, T., Wong, J., Abhayaratna, W., et al. (2018) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2018.06.1042 · Cited by 431
Erratum: Cardiotoxicity of anticancer treatments
Ewer, M. S., & Ewer, S. M. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.133 · Cited by 340
Self-citationPyroptosis in health and disease: mechanisms, regulation and clinical perspective
Liu, Y., Pan, R., Ouyang, Y., Gu, W., Xiao, T., Yang, H., Tang, L., Wang, H., Xiang, B., & Chen, P. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01958-2 · Cited by 337
Metadata
- Authors
- Ewer, M. S., & Ewer, S. M.
- Venue
- Nature Reviews Cardiology
- Published
- 2015-05-12
- Volume
- 12
- Issue
- 9
- Pages
- 547-558
- ISSN
- 1759-5002 (ISSN-L)
- 1759-5010
- OpenAlex
- W4211264672
- Cited by
- 415
- References
- 83
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.